A Novel Murine Model Enabling rAAV8-PC Gene Therapy for Severe Protein C Deficiency
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms251910336 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Sarina Levy-Mendelovich und 7 weiteren Autor:innen. Beteiligte Einrichtung: National Hemophilia Center, Thrombosis & Hemostasis Institute, Sheba Medical Center, Ramat Gan 52621, Israel. Hauptthemen laut MEDLINE: Genetic Therapy, Dependovirus, Disease Models, Animal, Genetic Vectors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, BSF, ARC.
Abstract (Originalsprache)
Severe protein C deficiency (SPCD) is a rare inherited thrombotic disease associated with high morbidity and mortality. In the current study, we established a viable murine model of SPCD, enabling preclinical gene therapy studies. By creating SPCD mice with severe hemophilia A (PROC−/−/F8−), the multi-month survival of SPCD mice enabled the exploration of recombinant adeno-associated viral vector-PC (rAAV8-PC) gene therapy (GT). rAAV8- PC (1012 vg/kg of AAV8-PC) was injected via the tail vein into 6–8-week-old PROC−/−/F8- mice. Their plasma PC antigen levels (median of 714 ng/mL, range 166–2488 ng/mL) and activity (303.5 ± 59%) significantly increased to the normal range after GT compared to untreated control animals. PC’s presence in the liver after GT was also confirmed by immunofluorescence staining. Our translational research results provide the first proof of concept that an infusion of rAAV8-PC increases PC antigen and activity in mice and may contribute to future GT in SPCD. Further basic research of SPCD mice with prolonged survival due to the rebalancing of this disorder using severe hemophilia A may provide essential data regarding PC’s contribution to specific tissues’ development, local PC generation, and its regulation in inflammatory conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Hemophilia Center, Thrombosis & Hemostasis Institute, Sheba Medical Center, Ramat Gan 52621, Israel.
- Amalia Biron Research Institute of Thrombosis & Hemostasis, Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv 6997801, Israel.
- Talpiot Medical Leadership Program, Sheba Medical Center, Ramat Gan 52621, Israel.
- Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
- Division of Hematology, Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
ORCID-Profile: Sarina Levy-Mendelovich, Einat Avishai, Benjamin J Samelson-Jones, Tami Brutman-Barazani, Tami Livnat, Gili Kenet
Förderung
- NHLBI NIH HHS
- BSF
- ARC
- Research authority, Sheba medical center
Zitieren
APA
Levy-Mendelovich, S., Avishai, E., Samelson-Jones, B. J., Dardik, R., Brutman-Barazani, T., Nisgav, Y., Livnat, T., & Kenet, G. (2024). A Novel Murine Model Enabling rAAV8-PC Gene Therapy for Severe Protein C Deficiency. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms251910336
Vancouver
Levy-Mendelovich S, Avishai E, Samelson-Jones BJ, Dardik R, Brutman-Barazani T, Nisgav Y, et al. A Novel Murine Model Enabling rAAV8-PC Gene Therapy for Severe Protein C Deficiency. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms251910336
BibTeX
@article{LevyMendelovich2024,
author = {Levy-Mendelovich, Sarina and Avishai, Einat and Samelson-Jones, Benjamin J and Dardik, Rima and Brutman-Barazani, Tami and Nisgav, Yael and Livnat, Tami and Kenet, Gili},
title = {A Novel Murine Model Enabling rAAV8-PC Gene Therapy for Severe Protein C Deficiency},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms251910336}
}
EUVIMED